Alumis raises $250m in IPO as biotech stock stirs [Yahoo! Finance]
CG Oncology, Inc. (CGON)
Company Research
Source: Yahoo! Finance
Formerly known as Esker Therapeutics, Alumis sold 13,125,000 shares for $16 each, as per a 27 June press release. The pricing is at the lower end of a previously announced price range in an SEC filing. The immunology company had originally expected proceeds of $274m in an IPO landscape that is reawakening following a lull over the past few years. The $16 per share pricing values the company at around $902m, according to Reuters Alumis will begin trading on Nasdaq today [28 June], under the symbol ALMS. The offering is expected to close on 1 July. Earlier this month, the US-based biotech said that it planned to use part of the IPO proceeds to advance its lead asset ESK-001 into multiple Phase III trials for moderate to severe plaque psoriasis treatment. ESK-001 is a tyrosine kinase 2 (TYK2) inhibitor. Alumis currently has an ongoing Phase II trial that is testing ESK-001 as a treatment for the autoimmune disease systemic lupus erythematosus. A-005, also a TYK2 inhibitor, is
Show less
Read more
Impact Snapshot
Event Time:
CGON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGON alerts
High impacting CG Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CGON
News
- CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $65.00 price target on the stock.MarketBeat
- Zenas BioPharma Weighs $150 Million-Plus IPO as Soon as July [Yahoo! Finance]Yahoo! Finance
- Zenas BioPharma Weighs $150 Million-Plus IPO as Soon as July [BNN Bloomberg (Canada)]BNN Bloomberg
- This year's IPO market got off to a roaring start. Now some fear it's out of gas [Yahoo! Finance]Yahoo! Finance
- This year's IPO market got off to a roaring start. Now some fear it's out of gas [Fortune]Fortune
CGON
Sec Filings
- 5/24/24 - Form 8-K
- 5/16/24 - Form 4
- 5/16/24 - Form 3
- CGON's page on the SEC website